Target cGMP-Enzyme Regulation System to treat aging-related diseases.
Aging processes are characterized by a reduction in blood circulation and dysregulation in cell-cell communication. The misbalance of cGMP levels leads to diseases like chronic wounds, skin fibrosis, age-related macula degeneration, diabetic retinopathy, colorectal cancer, hair loss and skin aging.
TOPADUR designed new drugs that target the cGMP-Enzyme Regulation System. TOPADUR’s compounds regulate the activity of sGC and PDE5 enzymes to increase the level of cGMP. This ultimately enables blood circulation and corrects the insufficient cell-cell communication.
Thormann et al, Formulation And Dermal Delivery Of A New Active Pharmaceutical Ingredient In An In Vitro Wound Model For The Treatment Of Chronic Ulcers. Eur J Pharm Biopharm (2024), doi: 10.1016/j.ejpb.2024.114373.
Rudgalvyte et al, Dual-Acting Nitric Oxide Donor And Phosphodiesterase Inhibitor TOP-N53 Increases Lifespan And Health Span Of Caenorhabditis Elegans. MicroPubl Biol. (2024), doi:10.17912/micropub.biology.001090.
Kim et al. Hair Follicle Targeting Delivery of Vasodilator TOP M119 via Dissolving Microneedle for Advanced Alopecia Treatment. Adv. Therap. (2022), doi:10.1002/adtp.202200052.
Martinez et al. A Dual-Acting Nitric Oxide Donor and Phosphodiesterase 5 Inhibitor Activates Autophagy in Primary Skin Fibroblasts. Int.J. Mol. Sci. (2022), doi: 10.3390/ijms23126860.
Ben-Yehuda Greenwald et al. Topical Wound Treatment with a Nitric Oxide-Releasing PDE5 Inhibitor Formulation Enhances Blood Perfusion and Promotes Healing in Mice. Pharmaceutics(2022), doi: 10.3390/pharmaceutics14112358.
Ben-Yehuda Greenwald et al. A Dual-Acting Nitric Oxide Donor and Phosphodiesterase 5Inhibitor Promotes Wound Healing in Normal Mice and Mice with Diabetes. Journalof Investigative Dermatology (2021), doi: 10.1016/j.jid.2020.05.111.
Naef, Tenor & Koch. TOP-N53: A Clinical Drug Candidate for the Treatment of Non-healing Wounds. Chimia 74 (2020), doi: 10.2533/chimia.2020.814.